Actively Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-04-07
75
Participants Needed
78
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
CONDITIONS
Official Title
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed or relapsing ANCA-associated vasculitis with GPA or MPA subtypes as per 2022 ACR/EULAR criteria
- Positive test for PR3-ANCA or MPO-ANCA antibodies at screening or previously by quantitative assay
- At least one major, or three minor, or two renal items in the Birmingham Vasculitis Activity Score (BVAS)
You will not qualify if you...
- Other systemic diseases including eosinophilic granulomatosis with polyangiitis, systemic lupus erythematosus, IgA nephropathy or vasculitis, rheumatoid vasculitis, Sjogren's syndrome, anti-GBM disease, cryoglobulinemic vasculitis, autoimmune hemolytic anemia, or mixed connective tissue disease
- Alveolar hemorrhage requiring invasive pulmonary ventilation at screening
- Any condition posing substantial clinical risk as judged by the investigator
- Patients with chronic kidney disease (CKD) who have stable eGFR for over 3 months and less than 25% decline at screening are excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 78 locations
1
Research Site
Ciudad de Buenos Aires, Argentina, C1015ABO
Actively Recruiting
2
Research Site
Ciudad de Buenos Aires, Argentina, C1181ACH
Actively Recruiting
3
Research Site
La Plata, Argentina, B1900AXI
Actively Recruiting
4
Research Site
Rosario, Argentina, S2000DEJ
Actively Recruiting
5
Research Site
San Juan Bautista, Argentina, 1888
Actively Recruiting
6
Research Site
Santa Fe, Argentina, S3000
Withdrawn
7
Research Site
Clayton, Australia, 3168
Not Yet Recruiting
8
Research Site
Heidelberg, Australia, 3084
Actively Recruiting
9
Research Site
Nedlands, Australia, 6009
Actively Recruiting
10
Research Site
Wollongong, Australia, 2500
Actively Recruiting
11
Research Site
Barretos, Brazil, 14784-057
Actively Recruiting
12
Research Site
Belo Horizonte, Brazil, 30130-100
Actively Recruiting
13
Research Site
Porto Alegre, Brazil, 90035-903
Actively Recruiting
14
Research Site
Recife, Brazil, 50670-420
Not Yet Recruiting
15
Research Site
São Paulo, Brazil, 01323-001
Actively Recruiting
16
Research Site
São Paulo, Brazil, 04038-002
Actively Recruiting
17
Research Site
São Paulo, Brazil, 05430-010
Actively Recruiting
18
Research Site
Calgary, Alberta, Canada, T2N 1N4
Not Yet Recruiting
19
Research Site
Edmonton, Alberta, Canada, T6G 2X8
Actively Recruiting
20
Research Site
Etobicoke, Ontario, Canada, M9W 6V1
Actively Recruiting
21
Research Site
Hamilton, Ontario, Canada, L8N 4A6
Not Yet Recruiting
22
Research Site
Toronto, Ontario, Canada, M5T 3L9
Actively Recruiting
23
Research Site
Montreal, Quebec, Canada, H4J 1C5
Not Yet Recruiting
24
Research Site
Baotou, China, 014010
Not Yet Recruiting
25
Research Site
Beijing, China, 100034
Actively Recruiting
26
Research Site
Beijing, China, 100730
Not Yet Recruiting
27
Research Site
Guangzhou, China, 510080
Actively Recruiting
28
Research Site
Hangzhou, China, 310003
Not Yet Recruiting
29
Research Site
Nanchang, China, 330006
Not Yet Recruiting
30
Research Site
Shenzhen, China, 518036
Not Yet Recruiting
31
Research Site
Marseille, France, 13385
Actively Recruiting
32
Research Site
Paris, France, 75014
Actively Recruiting
33
Research Site
Paris, France, 75015
Actively Recruiting
34
Research Site
Strasbourg, France, 67091
Actively Recruiting
35
Research Site
Toulouse, France, 31059
Actively Recruiting
36
Research Site
Berlin, Germany, 10117
Actively Recruiting
37
Research Site
Essen, Germany, 45147
Actively Recruiting
38
Research Site
Göttingen, Germany, 37075
Actively Recruiting
39
Research Site
Ludwigshafen, Germany, 67063
Actively Recruiting
40
Research Site
München, Germany, 81377
Actively Recruiting
41
Research Site
Brescia, Italy, 25123
Actively Recruiting
42
Research Site
Padova, Italy, 35128
Actively Recruiting
43
Research Site
Pavia, Italy, 27100
Actively Recruiting
44
Research Site
Pisa, Italy, 56126
Actively Recruiting
45
Research Site
Gdansk, Poland, 80-214
Actively Recruiting
46
Research Site
Krakow, Poland, 30-688
Actively Recruiting
47
Research Site
Poznan, Poland, 60-355
Actively Recruiting
48
Research Site
Warsaw, Poland, 04-141
Actively Recruiting
49
Research Site
Daegu, South Korea, 41944
Withdrawn
50
Research Site
Daegu, South Korea, 42472
Actively Recruiting
51
Research Site
Daejeon, South Korea, 35015
Actively Recruiting
52
Research Site
Seoul, South Korea, 03080
Actively Recruiting
53
Research Site
Seoul, South Korea, 03722
Actively Recruiting
54
Research Site
Seoul, South Korea, 04763
Actively Recruiting
55
Research Site
Seoul, South Korea, 08308
Actively Recruiting
56
Research Site
Seoul, South Korea, 135-710
Actively Recruiting
57
Research Site
Wŏnju, South Korea, 26426
Actively Recruiting
58
Research Site
Barcelona, Spain, 08036
Actively Recruiting
59
Research Site
Pamplona, Spain, 31008
Actively Recruiting
60
Research Site
San Sebastián de los Reyes, Spain, 28702
Actively Recruiting
61
Research Site
Santander, Spain, 39008
Actively Recruiting
62
Research Site
Seville, Spain, 41013
Actively Recruiting
63
Research Site
Kaohsiung City, Taiwan, 81362
Actively Recruiting
64
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
65
Research Site
Taipei, Taiwan, 114
Actively Recruiting
66
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
67
Research Site
Altındağ, Turkey (Türkiye), 06230
Actively Recruiting
68
Research Site
Ankara, Turkey (Türkiye), 5000
Actively Recruiting
69
Research Site
Center, Turkey (Türkiye), 23200
Actively Recruiting
70
Research Site
Istanbul, Turkey (Türkiye), 34098
Actively Recruiting
71
Research Site
Istanbul, Turkey (Türkiye)
Actively Recruiting
72
Research Site
Kocaeli, Turkey (Türkiye), 41380
Actively Recruiting
73
Research Site
Birmingham, United Kingdom, B15 2GW
Actively Recruiting
74
Research Site
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
75
Research Site
Leicester, United Kingdom, LE5 4PW
Not Yet Recruiting
76
Research Site
London, United Kingdom, NW3 2QG
Not Yet Recruiting
77
Research Site
London, United Kingdom, W12 0HS
Not Yet Recruiting
78
Research Site
Manchester, United Kingdom, M13 9WL
Not Yet Recruiting
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here